img

Global VMAT2 Inhibitors Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global VMAT2 Inhibitors Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Vesicular monoamine transporter-2 is the transmembrane protein which is primarily responsible for the transport of monoamines neurotransmitters such as histamines, serotonin, dopamine, and norepinephrine into the synaptic vesicles. VMAT2 transporter carries the cytoplasmic dopamine into the vesicles. VMAT2 inhibitors reduce the dopamine at the presynaptic striatal nerve terminals and decrease unwanted body movements for these conditions. VMAT2 inhibitors are widely used to treat uncontrollable involuntary, repetitive body movements caused by tardive dyskinesia and Huntington’s disease.
VMAT2 Inhibitors report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global VMAT2 Inhibitors market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Huntington’s Disease and Tardive Dyskinesia are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for VMAT2 Inhibitors industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, VMAT2 Inhibitors key manufacturers include Neurocrine Biosciences, Inc, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Hikma Pharmaceuticals plc, Hetero, Bausch Health Companies Inc, Dr. Reddy's Laboratories Ltd, Piramal Pharma Solution and Lupin, etc. Neurocrine Biosciences, Inc, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd are top 3 players and held % sales share in total in 2022.
VMAT2 Inhibitors can be divided into Tetrabenazine, Valbenazine and Other,, etc. Tetrabenazine is the mainstream product in the market, accounting for % sales share globally in 2022.
VMAT2 Inhibitors is widely used in various fields, such as Huntington’s Disease, Tardive Dyskinesia and Other,, etc. Huntington’s Disease provides greatest supports to the VMAT2 Inhibitors industry development. In 2022, global % sales of VMAT2 Inhibitors went into Huntington’s Disease filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global VMAT2 Inhibitors market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Neurocrine Biosciences, Inc
Teva Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd
Hikma Pharmaceuticals plc
Hetero
Bausch Health Companies Inc
Dr. Reddy's Laboratories Ltd
Piramal Pharma Solution
Lupin
Luye Pharma Group
Segment by Type
Tetrabenazine
Valbenazine
Other

Segment by Application


Huntington’s Disease
Tardive Dyskinesia
Other

Segment by Region


North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the VMAT2 Inhibitors market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of VMAT2 Inhibitors, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the VMAT2 Inhibitors industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of VMAT2 Inhibitors in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, VMAT2 Inhibitors introduction, etc. VMAT2 Inhibitors Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of VMAT2 Inhibitors market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.

Table of Content

1 VMAT2 Inhibitors Market Overview
1.1 VMAT2 Inhibitors Product Overview
1.2 VMAT2 Inhibitors Market Segment by Type
1.2.1 Tetrabenazine
1.2.2 Valbenazine
1.2.3 Other
1.3 Global VMAT2 Inhibitors Market Size by Type
1.3.1 Global VMAT2 Inhibitors Market Size Overview by Type (2024-2034)
1.3.2 Global VMAT2 Inhibitors Historic Market Size Review by Type (2024-2024)
1.3.3 Global VMAT2 Inhibitors Forecasted Market Size by Type (2024-2034)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America VMAT2 Inhibitors Sales Breakdown by Type (2024-2024)
1.4.2 Europe VMAT2 Inhibitors Sales Breakdown by Type (2024-2024)
1.4.3 Asia-Pacific VMAT2 Inhibitors Sales Breakdown by Type (2024-2024)
1.4.4 Latin America VMAT2 Inhibitors Sales Breakdown by Type (2024-2024)
1.4.5 Middle East and Africa VMAT2 Inhibitors Sales Breakdown by Type (2024-2024)
2 Global VMAT2 Inhibitors Market Competition by Company
2.1 Global Top Players by VMAT2 Inhibitors Sales (2024-2024)
2.2 Global Top Players by VMAT2 Inhibitors Revenue (2024-2024)
2.3 Global Top Players by VMAT2 Inhibitors Price (2024-2024)
2.4 Global Top Manufacturers VMAT2 Inhibitors Manufacturing Base Distribution, Sales Area, Product Type
2.5 VMAT2 Inhibitors Market Competitive Situation and Trends
2.5.1 VMAT2 Inhibitors Market Concentration Rate (2024-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by VMAT2 Inhibitors Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in VMAT2 Inhibitors as of 2022)
2.7 Date of Key Manufacturers Enter into VMAT2 Inhibitors Market
2.8 Key Manufacturers VMAT2 Inhibitors Product Offered
2.9 Mergers & Acquisitions, Expansion
3 VMAT2 Inhibitors Status and Outlook by Region
3.1 Global VMAT2 Inhibitors Market Size and CAGR by Region: 2024 VS 2022 VS 2034
3.2 Global VMAT2 Inhibitors Historic Market Size by Region
3.2.1 Global VMAT2 Inhibitors Sales in Volume by Region (2024-2024)
3.2.2 Global VMAT2 Inhibitors Sales in Value by Region (2024-2024)
3.2.3 Global VMAT2 Inhibitors Sales (Volume & Value) Price and Gross Margin (2024-2024)
3.3 Global VMAT2 Inhibitors Forecasted Market Size by Region
3.3.1 Global VMAT2 Inhibitors Sales in Volume by Region (2024-2034)
3.3.2 Global VMAT2 Inhibitors Sales in Value by Region (2024-2034)
3.3.3 Global VMAT2 Inhibitors Sales (Volume & Value), Price and Gross Margin (2024-2034)
4 Global VMAT2 Inhibitors by Application
4.1 VMAT2 Inhibitors Market Segment by Application
4.1.1 Huntington’s Disease
4.1.2 Tardive Dyskinesia
4.1.3 Other
4.2 Global VMAT2 Inhibitors Market Size by Application
4.2.1 Global VMAT2 Inhibitors Market Size Overview by Application (2024-2034)
4.2.2 Global VMAT2 Inhibitors Historic Market Size Review by Application (2024-2024)
4.2.3 Global VMAT2 Inhibitors Forecasted Market Size by Application (2024-2034)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America VMAT2 Inhibitors Sales Breakdown by Application (2024-2024)
4.3.2 Europe VMAT2 Inhibitors Sales Breakdown by Application (2024-2024)
4.3.3 Asia-Pacific VMAT2 Inhibitors Sales Breakdown by Application (2024-2024)
4.3.4 Latin America VMAT2 Inhibitors Sales Breakdown by Application (2024-2024)
4.3.5 Middle East and Africa VMAT2 Inhibitors Sales Breakdown by Application (2024-2024)
5 North America VMAT2 Inhibitors by Country
5.1 North America VMAT2 Inhibitors Historic Market Size by Country
5.1.1 North America VMAT2 Inhibitors Market Size Growth Rate (CAGR) by Country: 2024 VS 2022 VS 2034
5.1.2 North America VMAT2 Inhibitors Sales in Volume by Country (2024-2024)
5.1.3 North America VMAT2 Inhibitors Sales in Value by Country (2024-2024)
5.2 North America VMAT2 Inhibitors Forecasted Market Size by Country
5.2.1 North America VMAT2 Inhibitors Sales in Volume by Country (2024-2034)
5.2.2 North America VMAT2 Inhibitors Sales in Value by Country (2024-2034)
6 Europe VMAT2 Inhibitors by Country
6.1 Europe VMAT2 Inhibitors Historic Market Size by Country
6.1.1 Europe VMAT2 Inhibitors Market Size Growth Rate (CAGR) by Country: 2024 VS 2022 VS 2034
6.1.2 Europe VMAT2 Inhibitors Sales in Volume by Country (2024-2024)
6.1.3 Europe VMAT2 Inhibitors Sales in Value by Country (2024-2024)
6.2 Europe VMAT2 Inhibitors Forecasted Market Size by Country
6.2.1 Europe VMAT2 Inhibitors Sales in Volume by Country (2024-2034)
6.2.2 Europe VMAT2 Inhibitors Sales in Value by Country (2024-2034)
7 Asia-Pacific VMAT2 Inhibitors by Region
7.1 Asia-Pacific VMAT2 Inhibitors Historic Market Size by Region
7.1.1 Asia-Pacific VMAT2 Inhibitors Market Size Growth Rate (CAGR) by Region: 2024 VS 2022 VS 2034
7.1.2 Asia-Pacific VMAT2 Inhibitors Sales in Volume by Region (2024-2024)
7.1.3 Asia-Pacific VMAT2 Inhibitors Sales in Value by Region (2024-2024)
7.2 Asia-Pacific VMAT2 Inhibitors Forecasted Market Size by Region
7.2.1 Asia-Pacific VMAT2 Inhibitors Sales in Volume by Region (2024-2034)
7.2.2 Asia-Pacific VMAT2 Inhibitors Sales in Value by Region (2024-2034)
8 Latin America VMAT2 Inhibitors by Country
8.1 Latin America VMAT2 Inhibitors Historic Market Size by Country
8.1.1 Latin America VMAT2 Inhibitors Market Size Growth Rate (CAGR) by Country: 2024 VS 2022 VS 2034
8.1.2 Latin America VMAT2 Inhibitors Sales in Volume by Country (2024-2024)
8.1.3 Latin America VMAT2 Inhibitors Sales in Value by Country (2024-2024)
8.2 Latin America VMAT2 Inhibitors Forecasted Market Size by Country
8.2.1 Latin America VMAT2 Inhibitors Sales in Volume by Country (2024-2034)
8.2.2 Latin America VMAT2 Inhibitors Sales in Value by Country (2024-2034)
9 Middle East and Africa VMAT2 Inhibitors by Country
9.1 Middle East and Africa VMAT2 Inhibitors Historic Market Size by Country
9.1.1 Middle East and Africa VMAT2 Inhibitors Market Size Growth Rate (CAGR) by Country: 2024 VS 2022 VS 2034
9.1.2 Middle East and Africa VMAT2 Inhibitors Sales in Volume by Country (2024-2024)
9.1.3 Middle East and Africa VMAT2 Inhibitors Sales in Value by Country (2024-2024)
9.2 Middle East and Africa VMAT2 Inhibitors Forecasted Market Size by Country
9.2.1 Middle East and Africa VMAT2 Inhibitors Sales in Volume by Country (2024-2034)
9.2.2 Middle East and Africa VMAT2 Inhibitors Sales in Value by Country (2024-2034)
10 Company Profiles
10.1 Neurocrine Biosciences, Inc
10.1.1 Neurocrine Biosciences, Inc Company Information
10.1.2 Neurocrine Biosciences, Inc Introduction and Business Overview
10.1.3 Neurocrine Biosciences, Inc VMAT2 Inhibitors Sales, Revenue and Gross Margin (2024-2024)
10.1.4 Neurocrine Biosciences, Inc VMAT2 Inhibitors Products Offered
10.1.5 Neurocrine Biosciences, Inc Recent Development
10.2 Teva Pharmaceutical Industries Ltd
10.2.1 Teva Pharmaceutical Industries Ltd Company Information
10.2.2 Teva Pharmaceutical Industries Ltd Introduction and Business Overview
10.2.3 Teva Pharmaceutical Industries Ltd VMAT2 Inhibitors Sales, Revenue and Gross Margin (2024-2024)
10.2.4 Teva Pharmaceutical Industries Ltd VMAT2 Inhibitors Products Offered
10.2.5 Teva Pharmaceutical Industries Ltd Recent Development
10.3 Sun Pharmaceutical Industries Ltd
10.3.1 Sun Pharmaceutical Industries Ltd Company Information
10.3.2 Sun Pharmaceutical Industries Ltd Introduction and Business Overview
10.3.3 Sun Pharmaceutical Industries Ltd VMAT2 Inhibitors Sales, Revenue and Gross Margin (2024-2024)
10.3.4 Sun Pharmaceutical Industries Ltd VMAT2 Inhibitors Products Offered
10.3.5 Sun Pharmaceutical Industries Ltd Recent Development
10.4 Hikma Pharmaceuticals plc
10.4.1 Hikma Pharmaceuticals plc Company Information
10.4.2 Hikma Pharmaceuticals plc Introduction and Business Overview
10.4.3 Hikma Pharmaceuticals plc VMAT2 Inhibitors Sales, Revenue and Gross Margin (2024-2024)
10.4.4 Hikma Pharmaceuticals plc VMAT2 Inhibitors Products Offered
10.4.5 Hikma Pharmaceuticals plc Recent Development
10.5 Hetero
10.5.1 Hetero Company Information
10.5.2 Hetero Introduction and Business Overview
10.5.3 Hetero VMAT2 Inhibitors Sales, Revenue and Gross Margin (2024-2024)
10.5.4 Hetero VMAT2 Inhibitors Products Offered
10.5.5 Hetero Recent Development
10.6 Bausch Health Companies Inc
10.6.1 Bausch Health Companies Inc Company Information
10.6.2 Bausch Health Companies Inc Introduction and Business Overview
10.6.3 Bausch Health Companies Inc VMAT2 Inhibitors Sales, Revenue and Gross Margin (2024-2024)
10.6.4 Bausch Health Companies Inc VMAT2 Inhibitors Products Offered
10.6.5 Bausch Health Companies Inc Recent Development
10.7 Dr. Reddy's Laboratories Ltd
10.7.1 Dr. Reddy's Laboratories Ltd Company Information
10.7.2 Dr. Reddy's Laboratories Ltd Introduction and Business Overview
10.7.3 Dr. Reddy's Laboratories Ltd VMAT2 Inhibitors Sales, Revenue and Gross Margin (2024-2024)
10.7.4 Dr. Reddy's Laboratories Ltd VMAT2 Inhibitors Products Offered
10.7.5 Dr. Reddy's Laboratories Ltd Recent Development
10.8 Piramal Pharma Solution
10.8.1 Piramal Pharma Solution Company Information
10.8.2 Piramal Pharma Solution Introduction and Business Overview
10.8.3 Piramal Pharma Solution VMAT2 Inhibitors Sales, Revenue and Gross Margin (2024-2024)
10.8.4 Piramal Pharma Solution VMAT2 Inhibitors Products Offered
10.8.5 Piramal Pharma Solution Recent Development
10.9 Lupin
10.9.1 Lupin Company Information
10.9.2 Lupin Introduction and Business Overview
10.9.3 Lupin VMAT2 Inhibitors Sales, Revenue and Gross Margin (2024-2024)
10.9.4 Lupin VMAT2 Inhibitors Products Offered
10.9.5 Lupin Recent Development
10.10 Luye Pharma Group
10.10.1 Luye Pharma Group Company Information
10.10.2 Luye Pharma Group Introduction and Business Overview
10.10.3 Luye Pharma Group VMAT2 Inhibitors Sales, Revenue and Gross Margin (2024-2024)
10.10.4 Luye Pharma Group VMAT2 Inhibitors Products Offered
10.10.5 Luye Pharma Group Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 VMAT2 Inhibitors Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 VMAT2 Inhibitors Industrial Chain Analysis
11.4 VMAT2 Inhibitors Market Dynamics
11.4.1 VMAT2 Inhibitors Industry Trends
11.4.2 VMAT2 Inhibitors Market Drivers
11.4.3 VMAT2 Inhibitors Market Challenges
11.4.4 VMAT2 Inhibitors Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 VMAT2 Inhibitors Distributors
12.3 VMAT2 Inhibitors Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of Tetrabenazine
Table 2. Major Company of Valbenazine
Table 3. Major Company of Other
Table 4. Global VMAT2 Inhibitors Sales by Type 2024 VS 2022 VS 2034 (US$ Million)
Table 5. Global VMAT2 Inhibitors Sales by Type (2024-2024) & (K Units)
Table 6. Global VMAT2 Inhibitors Sales Market Share in Volume by Type (2024-2024)
Table 7. Global VMAT2 Inhibitors Sales by Type (2024-2024) & (US& Million)
Table 8. Global VMAT2 Inhibitors Market Share in Value by Type (2024-2024)
Table 9. Global VMAT2 Inhibitors Price by Type (2024-2024) & (US$/Unit)
Table 10. Global VMAT2 Inhibitors Sales by Type (2024-2034) & (K Units)
Table 11. Global VMAT2 Inhibitors Sales Market Share in Volume by Type (2024-2034)
Table 12. Global VMAT2 Inhibitors Sales by Type (2024-2034) & (US$ Million)
Table 13. Global VMAT2 Inhibitors Sales Market Share in Value by Type (2024-2034)
Table 14. Global VMAT2 Inhibitors Price by Type (2024-2034) & (US$/Unit)
Table 15. North America VMAT2 Inhibitors Sales by Type (2024-2024) & (K Units)
Table 16. North America VMAT2 Inhibitors Sales by Type (2024-2024) & (US$ Million)
Table 17. Europe VMAT2 Inhibitors Sales (K Units) by Type (2024-2024)
Table 18. Europe VMAT2 Inhibitors Sales by Type (2024-2024) & (US$ Million)
Table 19. Asia-Pacific VMAT2 Inhibitors Sales (K Units) by Type (2024-2024)
Table 20. Asia-Pacific VMAT2 Inhibitors Sales by Type (2024-2024) & (US$ Million)
Table 21. Latin America VMAT2 Inhibitors Sales (K Units) by Type (2024-2024)
Table 22. Latin America VMAT2 Inhibitors Sales by Type (2024-2024) & (US$ Million)
Table 23. Middle East and Africa VMAT2 Inhibitors Sales (K Units) by Type (2024-2024)
Table 24. Middle East and Africa VMAT2 Inhibitors Sales by Type (2024-2024) & (US$ Million)
Table 25. Global VMAT2 Inhibitors Sales by Company (2024-2024) & (K Units)
Table 26. Global VMAT2 Inhibitors Sales Share by Company (2024-2024)
Table 27. Global VMAT2 Inhibitors Revenue by Company (2024-2024) & (US$ Million)
Table 28. Global VMAT2 Inhibitors Revenue Share by Company (2024-2024)
Table 29. Global Market VMAT2 Inhibitors Price by Company (2024-2024) & (US$/Unit)
Table 30. Global VMAT2 Inhibitors Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 31. Global VMAT2 Inhibitors Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 32. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in VMAT2 Inhibitors as of 2022)
Table 33. Date of Key Manufacturers Enter into VMAT2 Inhibitors Market
Table 34. Key Manufacturers VMAT2 Inhibitors Product Type
Table 35. Mergers & Acquisitions, Expansion Plans
Table 36. Global VMAT2 Inhibitors Market Size Comparison by Region (US$ Million): 2024 VS 2022 VS 2034
Table 37. Global VMAT2 Inhibitors Sales by Region (2024-2024) & (K Units)
Table 38. Global VMAT2 Inhibitors Sales Market Share in Volume by Region (2024-2024)
Table 39. Global VMAT2 Inhibitors Sales by Region (2024-2024) & (US$ Million)
Table 40. Global VMAT2 Inhibitors Sales Market Share in Value by Region (2024-2024)
Table 41. Global VMAT2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 42. Global VMAT2 Inhibitors Sales by Region (2024-2034) & (K Units)
Table 43. Global VMAT2 Inhibitors Sales Market Share in Volume by Region (2024-2034)
Table 44. Global VMAT2 Inhibitors Sales by Region (2024-2034) & (US$ Million)
Table 45. Global VMAT2 Inhibitors Sales Market Share in Value by Region (2024-2034)
Table 46. Global VMAT2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2034)
Table 47. Global VMAT2 Inhibitors Sales by Application: 2024 VS 2022 VS 2034 (US$ Million)
Table 48. Global VMAT2 Inhibitors Sales by Application (2024-2024) & (K Units)
Table 49. Global VMAT2 Inhibitors Sales Market Share in Volume by Application (2024-2024)
Table 50. Global VMAT2 Inhibitors Sales by Application (2024-2024) & (US$ Million)
Table 51. Global VMAT2 Inhibitors Sales Market Share in Value by Application (2024-2024)
Table 52. Global VMAT2 Inhibitors Price by Application (2024-2024) & (US$/Unit)
Table 53. Global VMAT2 Inhibitors Sales by Application (2024-2034) & (K Units)
Table 54. Global VMAT2 Inhibitors Sales Market Share in Volume by Application (2024-2034)
Table 55. Global VMAT2 Inhibitors Sales by Application (2024-2034) & (US$ Million)
Table 56. Global VMAT2 Inhibitors Sales Market Share in Value by Application (2024-2034)
Table 57. Global VMAT2 Inhibitors Price by Application (2024-2034) & (US$/Unit)
Table 58. North America VMAT2 Inhibitors Sales by Application (2024-2024) (K Units)
Table 59. North America VMAT2 Inhibitors Sales by Application (2024-2024) & (US$ Million)
Table 60. Europe VMAT2 Inhibitors Sales by Application (2024-2024) (K Units)
Table 61. Europe VMAT2 Inhibitors Sales by Application (2024-2024) & (US$ Million)
Table 62. Asia-Pacific VMAT2 Inhibitors Sales by Application (2024-2024) (K Units)
Table 63. Asia-Pacific VMAT2 Inhibitors Sales by Application (2024-2024) & (US$ Million)
Table 64. Latin America VMAT2 Inhibitors Sales by Application (2024-2024) (K Units)
Table 65. Latin America VMAT2 Inhibitors Sales by Application (2024-2024) & (US$ Million)
Table 66. Middle East and Africa VMAT2 Inhibitors Sales by Application (2024-2024) (K Units)
Table 67. Middle East and Africa VMAT2 Inhibitors Sales by Application (2024-2024) & (US$ Million)
Table 68. North America VMAT2 Inhibitors Sales by Country (2024-2024) & (K Units)
Table 69. North America VMAT2 Inhibitors Sales Market Share in Volume by Country (2024-2024)
Table 70. North America VMAT2 Inhibitors Sales by Country (2024-2024) & (US$ Million)
Table 71. North America VMAT2 Inhibitors Sales Market Share in Value by Country (2024-2024)
Table 72. North America VMAT2 Inhibitors Sales by Country (2024-2034) & (K Units)
Table 73. North America VMAT2 Inhibitors Sales Market Share in Volume by Country (2024-2034)
Table 74. North America VMAT2 Inhibitors Sales by Country (2024-2034) & (US$ Million)
Table 75. North America VMAT2 Inhibitors Sales Market Share in Value by Country (2024-2034)
Table 76. Europe VMAT2 Inhibitors Sales by Country (2024-2024) & (K Units)
Table 77. Europe VMAT2 Inhibitors Sales Market Share in Volume by Country (2024-2024)
Table 78. Europe VMAT2 Inhibitors Sales by Country (2024-2024) & (US$ Million)
Table 79. Europe VMAT2 Inhibitors Sales Market Share in Value by Country (2024-2024)
Table 80. Europe VMAT2 Inhibitors Sales by Country (2024-2034) & (K Units)
Table 81. Europe VMAT2 Inhibitors Sales Market Share in Volume by Country (2024-2034)
Table 82. Europe VMAT2 Inhibitors Sales by Country (2024-2034) & (US$ Million)
Table 83. Europe VMAT2 Inhibitors Sales Market Share in Value by Country (2024-2034)
Table 84. Asia-Pacific VMAT2 Inhibitors Sales by Region (2024-2024) & (K Units)
Table 85. Asia-Pacific VMAT2 Inhibitors Sales Market Share in Volume by Region (2024-2024)
Table 86. Asia-Pacific VMAT2 Inhibitors Sales by Region (2024-2024) & (US$ Million)
Table 87. Asia-Pacific VMAT2 Inhibitors Sales Market Share in Value by Region (2024-2024)
Table 88. Asia-Pacific VMAT2 Inhibitors Sales by Region (2024-2034) & (K Units)
Table 89. Asia-Pacific VMAT2 Inhibitors Sales Market Share in Volume by Region (2024-2034)
Table 90. Asia-Pacific VMAT2 Inhibitors Sales by Region (2024-2034) & (US$ Million)
Table 91. Asia-Pacific VMAT2 Inhibitors Sales Market Share in Value by Region (2024-2034)
Table 92. Latin America VMAT2 Inhibitors Sales by Country (2024-2024) & (K Units)
Table 93. Latin America VMAT2 Inhibitors Sales Market Share in Volume by Country (2024-2024)
Table 94. Latin America VMAT2 Inhibitors Sales by Country (2024-2024) & (US$ Million)
Table 95. Latin America VMAT2 Inhibitors Sales Market Share in Value by Country (2024-2024)
Table 96. Latin America VMAT2 Inhibitors Sales by Country (2024-2034) & (K Units)
Table 97. Latin America VMAT2 Inhibitors Sales Market Share in Volume by Country (2024-2034)
Table 98. Latin America VMAT2 Inhibitors Sales by Country (2024-2034) & (US$ Million)
Table 99. Latin America VMAT2 Inhibitors Sales Market Share in Value by Country (2024-2034)
Table 100. Middle East and Africa VMAT2 Inhibitors Sales by Country (2024-2024) & (K Units)
Table 101. Middle East and Africa VMAT2 Inhibitors Sales Market Share in Volume by Country (2024-2024)
Table 102. Middle East and Africa VMAT2 Inhibitors Sales by Country (2024-2024) & (US$ Million)
Table 103. Middle East and Africa VMAT2 Inhibitors Sales Market Share in Value by Country (2024-2024)
Table 104. Middle East and Africa VMAT2 Inhibitors Sales by Country (2024-2034) & (K Units)
Table 105. Middle East and Africa VMAT2 Inhibitors Sales Market Share in Volume by Country (2024-2034)
Table 106. Middle East and Africa VMAT2 Inhibitors Sales by Country (2024-2034) & (US$ Million)
Table 107. Middle East and Africa VMAT2 Inhibitors Sales Market Share in Value by Country (2024-2034)
Table 108. Neurocrine Biosciences, Inc Company Information
Table 109. Neurocrine Biosciences, Inc Introduction and Business Overview
Table 110. Neurocrine Biosciences, Inc VMAT2 Inhibitors Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2024-2024)
Table 111. Neurocrine Biosciences, Inc VMAT2 Inhibitors Product
Table 112. Neurocrine Biosciences, Inc Recent Development
Table 113. Teva Pharmaceutical Industries Ltd Company Information
Table 114. Teva Pharmaceutical Industries Ltd Introduction and Business Overview
Table 115. Teva Pharmaceutical Industries Ltd VMAT2 Inhibitors Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2024-2024)
Table 116. Teva Pharmaceutical Industries Ltd VMAT2 Inhibitors Product
Table 117. Teva Pharmaceutical Industries Ltd Recent Development
Table 118. Sun Pharmaceutical Industries Ltd Company Information
Table 119. Sun Pharmaceutical Industries Ltd Introduction and Business Overview
Table 120. Sun Pharmaceutical Industries Ltd VMAT2 Inhibitors Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2024-2024)
Table 121. Sun Pharmaceutical Industries Ltd VMAT2 Inhibitors Product
Table 122. Sun Pharmaceutical Industries Ltd Recent Development
Table 123. Hikma Pharmaceuticals plc Company Information
Table 124. Hikma Pharmaceuticals plc Introduction and Business Overview
Table 125. Hikma Pharmaceuticals plc VMAT2 Inhibitors Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2024-2024)
Table 126. Hikma Pharmaceuticals plc VMAT2 Inhibitors Product
Table 127. Hikma Pharmaceuticals plc Recent Development
Table 128. Hetero Company Information
Table 129. Hetero Introduction and Business Overview
Table 130. Hetero VMAT2 Inhibitors Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2024-2024)
Table 131. Hetero VMAT2 Inhibitors Product
Table 132. Hetero Recent Development
Table 133. Bausch Health Companies Inc Company Information
Table 134. Bausch Health Companies Inc Introduction and Business Overview
Table 135. Bausch Health Companies Inc VMAT2 Inhibitors Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2024-2024)
Table 136. Bausch Health Companies Inc VMAT2 Inhibitors Product
Table 137. Bausch Health Companies Inc Recent Development
Table 138. Dr. Reddy's Laboratories Ltd Company Information
Table 139. Dr. Reddy's Laboratories Ltd Introduction and Business Overview
Table 140. Dr. Reddy's Laboratories Ltd VMAT2 Inhibitors Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2024-2024)
Table 141. Dr. Reddy's Laboratories Ltd VMAT2 Inhibitors Product
Table 142. Dr. Reddy's Laboratories Ltd Recent Development
Table 143. Piramal Pharma Solution Company Information
Table 144. Piramal Pharma Solution Introduction and Business Overview
Table 145. Piramal Pharma Solution VMAT2 Inhibitors Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2024-2024)
Table 146. Piramal Pharma Solution VMAT2 Inhibitors Product
Table 147. Piramal Pharma Solution Recent Development
Table 148. Lupin Company Information
Table 149. Lupin Introduction and Business Overview
Table 150. Lupin VMAT2 Inhibitors Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2024-2024)
Table 151. Lupin VMAT2 Inhibitors Product
Table 152. Lupin Recent Development
Table 153. Luye Pharma Group Company Information
Table 154. Luye Pharma Group Introduction and Business Overview
Table 155. Luye Pharma Group VMAT2 Inhibitors Sales (K Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2024-2024)
Table 156. Luye Pharma Group VMAT2 Inhibitors Product
Table 157. Luye Pharma Group Recent Development
Table 158. Key Raw Materials Lists
Table 159. Raw Materials Key Suppliers Lists
Table 160. VMAT2 Inhibitors Market Trends
Table 161. VMAT2 Inhibitors Market Drivers
Table 162. VMAT2 Inhibitors Market Challenges
Table 163. VMAT2 Inhibitors Market Restraints
Table 164. VMAT2 Inhibitors Distributors List
Table 165. VMAT2 Inhibitors Downstream Customers
Table 166. Research Programs/Design for This Report
Table 167. Key Data Information from Secondary Sources
Table 168. Key Data Information from Primary Sources
List of Figures
Figure 1. VMAT2 Inhibitors Product Picture
Figure 2. Global VMAT2 Inhibitors Market Size, 2024 VS 2022 VS 2034 (US$ Million)
Figure 3. Global VMAT2 Inhibitors Market Size Status and Outlook (2024-2034) & (US$ Million)
Figure 4. Global VMAT2 Inhibitors Sales Status and Outlook (2024-2034) & (K Units)
Figure 5. Product Picture of Tetrabenazine
Figure 6. Global Tetrabenazine Sales YoY Growth (2024-2034) & (K Units)
Figure 7. Product Picture of Valbenazine
Figure 8. Global Valbenazine Sales YoY Growth (2024-2034) & (K Units)
Figure 9. Product Picture of Other
Figure 10. Global Other Sales YoY Growth (2024-2034) & (K Units)
Figure 11. Global VMAT2 Inhibitors Sales by Type (2024-2034) & (US$ Million)
Figure 12. Global VMAT2 Inhibitors Sales Market Share by Type in 2022 & 2034
Figure 13. North America VMAT2 Inhibitors Sales Market Share in Volume by Type in 2022
Figure 14. North America VMAT2 Inhibitors Sales Market Share in Value by Type in 2022
Figure 15. Europe VMAT2 Inhibitors Sales Market Share in Volume by Type in 2022
Figure 16. Europe VMAT2 Inhibitors Sales Market Share in Value by Type in 2022
Figure 17. Asia-Pacific VMAT2 Inhibitors Sales Market Share in Volume by Type in 2022
Figure 18. Asia-Pacific VMAT2 Inhibitors Sales Market Share in Value by Type in 2022
Figure 19. Latin America VMAT2 Inhibitors Sales Market Share in Volume by Type in 2022
Figure 20. Latin America VMAT2 Inhibitors Sales Market Share in Value by Type in 2022
Figure 21. Middle East and Africa VMAT2 Inhibitors Sales Market Share in Volume by Type in 2022
Figure 22. Middle East and Africa VMAT2 Inhibitors Sales Market Share in Value by Type in 2022
Figure 23. The 5 and 10 Largest Manufacturers in the World: Market Share by VMAT2 Inhibitors Sales in 2022
Figure 24. The 5 and 10 Largest Manufacturers in the World: Market Share by VMAT2 Inhibitors Revenue in 2022
Figure 25. VMAT2 Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2024 VS 2022
Figure 26. Product Picture of Huntington’s Disease
Figure 27. Global Huntington’s Disease Sales YoY Growth (2024-2034) & (K Units)
Figure 28. Product Picture of Tardive Dyskinesia
Figure 29. Global Tardive Dyskinesia Sales YoY Growth (2024-2034) & (K Units)
Figure 30. Product Picture of Other
Figure 31. Global Other Sales YoY Growth (2024-2034) & (K Units)
Figure 32. Global VMAT2 Inhibitors Sales by Application (2024-2034) & (US$ Million)
Figure 33. Global VMAT2 Inhibitors Sales Market Share by Application in 2022 & 2034
Figure 34. North America VMAT2 Inhibitors Sales Market Share in Volume by Application in 2022
Figure 35. North America VMAT2 Inhibitors Sales Market Share in Value by Application in 2022
Figure 36. Europe VMAT2 Inhibitors Sales Market Share in Volume by Application in 2022
Figure 37. Europe VMAT2 Inhibitors Sales Market Share in Value by Application in 2022
Figure 38. Asia-Pacific VMAT2 Inhibitors Sales Market Share in Volume by Application in 2022
Figure 39. Asia-Pacific VMAT2 Inhibitors Sales Market Share in Value by Application in 2022
Figure 40. Latin America VMAT2 Inhibitors Sales Market Share in Volume by Application in 2022
Figure 41. Latin America VMAT2 Inhibitors Sales Market Share in Value by Application in 2022
Figure 42. Middle East and Africa VMAT2 Inhibitors Sales Market Share in Value by Application in 2022
Figure 43. Key Raw Materials Price
Figure 44. VMAT2 Inhibitors Manufacturing Cost Structure
Figure 45. VMAT2 Inhibitors Industrial Chain Analysis
Figure 46. Channels of Distribution
Figure 47. Distributors Profiles
Figure 48. Bottom-up and Top-down Approaches for This Report
Figure 49. Data Triangulation
Figure 50. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries